> Skip repeated content
photo of Theresa Wampler Muskardin, MD

Theresa Wampler Muskardin, MD

Lerner Children's Pavilion at Hospital for Special Surgery logoPediatrics, Rheumatology

About Dr. Wampler Muskardin

Dr. Wampler Muskardin is an Assistant Professor of Medicine and Pediatrics in the Division of Rheumatology and a Clinical Research Scientist in the Research Institute at Hospital for Special Surgery. She has been certified by the American Board of Internal Medicine in Rheumatology and by the American Board of Pediatrics in Pediatric Rheumatology.

Dr. Wampler Muskardin sees both pediatric and adult patients. Particular areas of clinical expertise include autoinflammatory disorders, interferonopathies, and primary immune deficiencies with immune dysregulation. These diseases, which often have a strong genetic driver, lend insight into the biology of more complex/heterogenous rheumatic diseases. She has diagnosed and managed patients who have exceptionally rare disease and enjoys collaboration with colleagues at the NIH and elsewhere to provide the best care to patients. She also has expertise in inflammatory arthritis (e.g., Rheumatoid arthritis, Juvenile Idiopathic Arthritis, Spondyloarthropathies), systemic autoimmune connective tissue diseases (e.g., Sjogren's), and inflammatory bone diseases (e.g., Chronic Recurrent Multifocal Osteomyelitis).

Born in Detroit, Dr. Wampler Muskardin completed her MD training at Wayne State University School of Medicine. She then completed a combined residency in Internal Medicine and Pediatrics and combined fellowship in both adult and pediatric Rheumatology at the University of Minnesota, where she began research in Type I interferon (IFN) and toll-like receptor (TLR) pathways. After fellowship she became faculty at the Mayo Clinic in Rochester, MN, where she began training in the laboratory of Timothy Niewold, a Lupus genetics and type I IFN expert. She moved to New York in 2017 to continue her translational work at NYU Grossman School of Medicine/NYU Langone Health. She joined the faculty of HSS in 2022.


Specialized Centers

Inflammatory Arthritis Center

Special Expertise

Chronic recurrent multifocal osteomyelitis (CRMO)
Inflammatory disease associated with immune deficiency
Juvenile Idiopathic Arthritis
Chronic recurrent multifocal osteomyelitis (CRMO)
Monogenic autoinflammatory diseases (e.g., Muckle-Wells Syndrome, Familial Mediterranean Fever)
Rheumatoid arthritis
Still's disease
SAPHO (Synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome



Patient Stories


Please call our office if you have questions regarding your insurance coverage. If you have out of network benefits, then your insurance may reimburse you for a portion of your office visit. We will work with you and your insurance to minimize your out-of-pocket costs. Financial assistance may be available for patients in need.



Assistant Attending Physician, Hospital for Special Surgery
Clinical Research Scientist, Hospital for Special Surgery Research Institute
Assistant Professor of Medicine, Weill Cornell Medical College


Rheumatology Research Foundation Career Development Bridge Funding Award: K Bridge, 2021
Arthritis National Research Foundation Arthritis Research Award, 2019 (Sontag Foundation Fellow 2019 - 2020)
NYU-NYHH Clinical and Translational Science Institute KL2 Award, 2019
NYU Clinical and Translational Science Institute Scholar Award, 2018
American Federation for Medical Research Scholar Award, 2017
Central Society for Clinical and Translational Research Early Career Development Award, 2017


Medical School: Wayne State University School of Medicine Detroit, MI, 2004
Residency: Internal Medicine - Pediatrics Residency Program University of Minnesota Minneapolis, MN, 2008
Chief Resident, Department of Pediatrics University of Minnesota, 2009
Fellowship: Combined Rheumatology and Pediatric Rheumatology Fellowship Department of Pediatrics, Division of Pediatric Rheumatology Department of Medicine, Division of Rheumatic and Autoimmune Diseases University of Minnesota Minneapolis, MN, 2013


Wayne State University School of Medicine Detroit, MI, 2004


Internal Medicine, Pediatrics Residency Program University of Minnesota Minneapolis, MN, 2008
Chief Resident, Department of Pediatrics University of Minnesota, 2009


Department of Pediatrics, Division of Pediatric Rheumatology, University of Minnesota Minneapolis, MN, 2013
Department of Medicine, Division of Rheumatic and Autoimmune Diseases, University of Minnesota Minneapolis, MN,  2013

State Licensure



Publications by Dr. Wampler Muskardin

Selected Journal Articles

Schaefer LS, Wampler Muskardin T, Tillema JM, Wieland C, Tollefson MM. A fatal case of malignant atrophic papulosis in a pediatric patient. Pediatr Dermatol. 2021 Dec 21. doi: 10.1111/pde.14878. Online ahead of print. PMID: 34935194

Nln I, Fernandez-Ruiz R, Wampler Muskardin TL, Paredes JL, Blazer AD, Tuminello S, Attur M, Iturrate E, Petrilli CM, Abramson SB, Chakravarti A, Niewold TB. Interferon pathway lupus risk alleles modulate risk of death from acute COVID-19. medRxiv [Preprint]. 2021 Nov 2:2021.11.01.21265766. doi: 10.1101/2021.11.01.21265766. PMID: 34751274; PMCID: PMC8575145.

Reyes AZ, Hu KA, Teperman J, Wampler Muskardin TL, Tardif JC, Shah B, Pillinger MH. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. Ann Rheum Dis. 2020 Dec 8. doi: 10.1136/annrheumdis-2020-219174. PMID: 33293273

Wampler Muskardin T, Fan W, Jin Z, Jensen MA, Dorschner JM, Ghodke-Puranik Y, Wright K, Davis JM, Matteson EL, Michet C, Persellin ST, Schaffer D, Dicke B, Vsetecka D, Niewold TB. Distinct single cell gene expression in peripheral blood monocytes correlates with tumor necrosis factor inhibitor treatment response groups defined by type I interferon in rheumatoid arthritis. Front Immunol 2020 Jul 16;11:1384. doi: 10.3389/fimmu.2020.01384. eCollection 2020. PMID: 32765497 PMCID: PMC7378891

Wampler Muskardin T. Intravenous anakinra for macrophage activation syndrome may hold lessons for treatment of cytokine storm in the setting of coronavirus disease 2019. ACR Open Rheumatol. 2020 May;2(5):283-285. doi: 10.1002/acr2.11140. Epub 2020 May 10. PMID: 32267072

de Jesus AA, Hou Y, Brooks S, Malle L, Biancotto A, Huang Y, Calvo KR, Marrero B, Moir S, Oler AJ, Deng Z, Montealegre Sanchez GA, Ahmed A, Allenspach E, Arabshahi B, Behrens E, Benseler S, Bezrodnik L, Bout-Tabaku S, Brescia AC, Brown D, Burnham JM, Caldirola MS, Carrasco R, Chan AY, Cimaz R, Dancey P, Dare J, DeGuzman M, Dimitriades V, Ferguson I, Ferguson P, Finn L, Gattorno M, Grom AA, Hanson EP, Hashkes PJ, Hedrich CM, Herzog R, Horneff G, Jerath R, Kessler E, Kim H, Kingsbury DJ, Laxer RM, Lee PY, Lee-Kirsch MA, Lewandowski L, Li S, Lilleby V, Mammadova V, Moorthy LN, Nasrullayeva G, O'Neil KM, Onel K, Ozen S, Pan N, Pillet P, Piotto DG, Punaro MG, Reiff A, Reinhardt A, Rider LG, Rivas-Chacon R, Ronis T, R sen-Wolff A, Roth J, Ruth NM, Rygg M, Schmeling H, Schulert G, Scott C, Seminario G, Shulman A, Sivaraman V, Son MB, Stepanovskyy Y, Stringer E, Taber S, Terreri MT, Tifft C, Torgerson T, Tosi L, Van Royen-Kerkhof A, Wampler Muskardin T, Canna SW, Goldbach-Mansky R.. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. J Clin Invest. 2020 Apr 1;130(4):1669-1682. doi: 10.1172/JCI129301. PMID: 31874111

Wampler Muskardin T, Paredes JL, Appenzeller S, Niewold TB. Lessons from Precision Medicine in Rheumatology. Mult Scler. 2020 Jan 22:1352458519884249. doi: 10.1177/1352458519884249. [Epub ahead of print] PMID: 31965913

Muskardin TLW and Niewold T. Type I interferons in rheumatic disease. Nat Rev Rheum. 2018 Mar 21;14(4):214- 228. doi: 10.1038/nrrheum.2018.31. Review. PMID: 29559718

Wampler Muskardin T, Vashisht P, Dorschner JM, Jensen MA, Chrabot BS, Kern M, Curtis JR, Danila MI, Cofield SS, Shadick N, Nigrovic P, St. Clair EW, Bingham CO, Furie R, Robinson W, Genovese M, Striebich C, O'Dell JR, Thiele G, Moreland LW, Levesque M, Bridges SL, Gregersen PK, Niewold TB. Increased pre-treatment serum IFN-β/α ratio predicts non-response to tumor necrosis factor alpha inhibition in rheumatoid arthritis. Ann Rheum Dis. 2016 Oct;75(10):1757-62. doi: 10.1136/annrheumdis-2015-208001. PMID: 26546586

Kenney-Jung DL, Vezzani A, Kahoud RJ, LaFrance-Corey RG, Ho ML, Wampler Muskardin T, Wirrell EC, Howe CL, Payne ET. Febrile infection-related epilepsy syndrome treated with anakinra. Ann Neurol. 2016 Oct 22. doi: 10.1002/ana/24806 PMID: 27770579

For more publications, please see the PubMed listing.

Selected Presentations

October 19, 2021 (Cardiff, UK) November 6, 2021 (US) (Virtual) "Vascularized 'Synovium-on-a-Chip' - a Novel and Adaptable Model for Dissecting Inflammatory Biology Underlying Rheumatoid Arthritis" Theresa Wampler Muskardin, Chao Ma, Benteng Ma, Kayla VanBuren, Timothy Niewold, and Weiqiang Chen. Cytokines 2021 Hybrid, 9th Annual Meeting of the International Cytokine & Interferon Society (ICIS). American College of Rheumatology (ACR) Convergence 2021

Oct 22, 2021 (Virtual) "Toward Precision Medicine – Type I Interferon and Prediction of Treatment Response in Rheumatoid Arthritis." Invited lecture. Arthritis National Research Foundation (ANRF) Researcher Spotlight Series – RA.

Sept 2, 2020 (Virtual) "Type I IFNs in Health and Disease/COVID-19" Invited lecture. Basic and Clinical Immunology for the Busy Clinician Course – in the Zoom/COVID-19 Era. R.J. Fasenmyer Center for Clinical Immunology. Cleveland Clinic.

Sept 23, 2019 Stockholm, SWE "Type I IFNs and IFN Pathway in Prediction of Treatment Response in Rheumatoid Arthritis." Invited lecture. 25th Mayo-Karolinska Institute Annual Scientific Research Meeting.

March 13, 2019 New York, NY "Type I Interferon in Rheumatic Disease." Pediatric Rheumatology: An Update for Clinicians. NYU Continuing Medical Education Course.

October 30, 2017 Kanazawa, JPN "Distinct single cell gene expression signatures of monocyte subsets differentiate between TNF-alpha inhibitor treatment response groups in Rheumatoid Arthritis" Wampler Muskardin T, Fan W, Jin Z, Jensen MA, Dorschner JM, Ghodke-Puranik Y, the Mayo Clinic Inflammatory Arthritis Clinic, Dicke B, Vsetecka D, Niewold TB. Oral abstract in "Precision Immunology" session, 5th Annual Meeting of the International Cytokine and Interferon Society.

December 9, 2016 Rochester, MN "Prediction of Treatment Response in the Era of Biologics." Wampler Muskardin T. Invited lecture. Grand Rounds, Department of Pediatric and Adolescent Medicine, Mayo Clinic.


Dr. Wampler Muskardin is a clinician-scientist who focuses on disease heterogeneity and precision medicine in rheumatoid arthritis (RA). She uses cell biology and immunology to understand differences among patients and to discover biomarkers that allow for more rational personalized treatment strategies. The intent is to be able to tailor therapy to an individual's disease process and personal immunology.

During fellowship, Dr. Wampler Muskardin cultivated her interest in understanding key biological differences between patients by studying the type I interferon (T1IFN) pathway. She then joined the faculty at the Mayo Clinic, where she became a mentee of Timothy Niewold, a clinician-scientist and expert in SLE genetics and T1IFN. By refining the functional T1IFN assay previously developed by the Niewold laboratory to include measurement of the major type I IFN subtypes and applying this assay in the study of sera from two independent cohorts of patients with RA, Dr. Wampler Muskardin and colleagues have been able to break new ground in biomarker discovery and understanding of treatment response in RA. She has published papers related to this work in leading journals (Annals of Rheumatic Disease, Nature Reviews Rheumatology, Frontiers in Immunology). Currently, Dr. Wampler Muskardin and collaborators are pursuing novel approaches to study patients who have RA to understand key differences among patients that inform treatment response. This would enable new personalized treatment strategies capable of inhibiting disease progression and restoring health. At Hospital for Special Surgery, Dr. Wampler Muskardin is a member of the Inflammatory Arthritis Center of Excellence, which allows patients to participate in translational and clinical research studies.

Dr. Wampler Muskardin's research focuses on human studies of type I IFN and cell biology in understanding response to treatment in inflammatory arthritis. She aims to understand differences among patients and to discover biomarkers that allow for prognostication and more rational, personalized treatment strategies. The major focus of her current work is on understanding differences in treatment response in Rheumatoid Arthritis (RA). She has also studied the type I interferon pathway in other rheumatic diseases (systemic lupus erythematosus, systemic scleroderma, juvenile idiopathic arthritis, dermatomyositis, interferonopathies).

She has received benefactor-funded Career Development and Innovative Rheumatoid Arthritis Research awards, an Arthritis National Research Foundation Arthritis Research Award, Doris Duke Fund to Retain Clinician Scientist Awards, a NYU Clinical & Translational Science Institute KL2 Award, and a Rheumatology Research Foundation K Bridge Award. She has presented nationally and internationally, including talks at the annual scientific meetings of the American College of Rheumatology (ACR), the Federation of Clinical Immunological Societies (FOCiS), and the International Cytokine & Interferon Society (ICIS). Dr. Wampler Muskardin maintains active membership in the ACR, FOCiS, ICIS, and the Childhood Arthritis & Rheumatology Research Alliance (CARRA). She has served on the CARRA steering committee, served as a member of the CARRA strategic planning committee, and continues to be a member of the CARRA Translational Research and Technology Committee and the CARRA Autoinflammatory Network Development Workgroup.

Industry Relationships

Industry Relationships

One of the goals of HSS is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.

As part of the disclosure process, this website lists physician collaborations with outside companies. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.

As of February 01, 2022, Dr. Wampler Muskardin reported no relationships with healthcare industry.

By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.

Call for an appointment